If someone invites you to their meeting, you can join without creating or signing in to an account. Our work provides a proof of therapeutic utility for a novel strategy to inhibit transcription factor activity, through interference with a node of protein-protein interactions, re-establishing transcription factors as a viable class of molecular targets for small molecules in therapeutic settings.You do not need a Zoom account to join meetings as a participant. Further, using this new strategy we have identified a FDA-approved drug that has been successfully repurposed to manage two rare vascular disorders in Human. During the presentation, I will show a novel molecular strategy that is efficient to interfere with the SOX18 TF activity to perturb vascular outgrowth in pre-clinical model systems. However, isolating and targeting one specific interaction is often insufficient to generate a biological effect, due to redundancies in regulatory pathways in which transcription factors are involved. Many transcription factors depend on interactions with partner proteins for their activity, and so attempts to develop therapeutics have focused on disrupting interactions critical for nuclear shuttling, post-translational modification or dimerization.

Abstract: Modulation of transcription factor (TF) activity holds great promise for the development of targeted therapeutics, because these proteins act at the point of convergence for cell signaling and directly orchestrate gene expression.

Join a zoom meeting with meeting id